专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US11850245B2 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 有权
公开(公告)号：US11850245B2
公开(公告)日：2023-12-26
申请号：US17177116
申请日：2021-02-16
申请人： Medicis Pharmaceutical Corporation
发明人： Michael T. Nordsiek , Jefferson J. Gregory
IPC分类号： A61K9/00 , A61K9/06 , A61K31/44 , A61K47/10 , A61K47/12 , A61K31/4745
CPC分类号： A61K31/4745 , A61K9/0014 , A61K31/44 , A61K47/10 , A61K47/12 , A61K9/06
摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

2. 发明授权

US10918635B2 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 有权
公开(公告)号：US10918635B2
公开(公告)日：2021-02-16
申请号：US16364023
申请日：2019-03-25
申请人： Medicis Pharmaceutical Corporation
发明人： Michael T. Nordsiek , Jefferson J. Gregory
IPC分类号： A61K9/00 , A61K9/06 , A61K31/44 , A61K47/10 , A61K47/12 , A61K31/4745
摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.

3. 发明授权

US09561241B1 Gastroretentive dosage forms for minocycline 有权
标题翻译：米诺环素的胃酸剂型
公开(公告)号：US09561241B1
公开(公告)日：2017-02-07
申请号：US13536130
申请日：2012-06-28
申请人： Douglas A. Bakan , Waranush Jitpraphai , Steven B. Newhard , Mitchell S. Wortzman
发明人： Douglas A. Bakan , Waranush Jitpraphai , Steven B. Newhard , Mitchell S. Wortzman
IPC分类号： A61K9/48 , A61K9/00 , A61K9/20 , A01N37/18 , A61K31/65
CPC分类号： A61K31/65 , A61K9/0004 , A61K9/0065 , A61K9/2054 , A61K9/4858
摘要： The present disclosure relates to dosage forms and methods that enhance the absorption of minocycline in the gastrointestinal tract and thereby enhance bioavailability of the minocycline, and further provides methods of using these dosage forms for the treatment of conditions such as acne.
摘要翻译：本公开涉及增加米诺环素在胃肠道中的吸收并从而增强米诺环素的生物利用度的剂型和方法，并且还提供使用这些剂型用于治疗诸如痤疮等病症的方法。

4. 发明授权

US09370509B2 2×2×2 week dosing regimen for treating actinic keratosis with pharmaceutical compositions formulated with 3.75 % imiquimod 有权
标题翻译： 2×2×2周给药方案，用3.75％咪喹莫特配制的药物组合物治疗光化性角化病
公开(公告)号：US09370509B2
公开(公告)日：2016-06-21
申请号：US13568003
申请日：2012-08-06
申请人： Michael T. Nordsiek , Sharon F. Levy , James H. Lee , James H. Kulp , Kodumudi S. Balaji , Tze-Chiang Meng , Jason J. Wu , Valyn S. Bahm , Robert Babilon
发明人： Michael T. Nordsiek , Sharon F. Levy , James H. Lee , James H. Kulp , Kodumudi S. Balaji , Tze-Chiang Meng , Jason J. Wu , Valyn S. Bahm , Robert Babilon
IPC分类号： A61K31/4745 , A61K31/47 , A61K31/437 , A61K47/10 , A61K9/06 , A61K9/00 , A61K9/70 , A61K47/12 , A61K47/14
CPC分类号： A61K31/4745 , A61K9/0014 , A61K9/06 , A61K9/7061 , A61K31/437 , A61K31/47 , A61K47/10 , A61K47/12 , A61K47/14
摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
摘要翻译：用于局部或透皮递送1-异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c] 喹诺酮-4-胺，即咪喹莫特，用于治疗短暂持续时间的光化性角化病，比现在由美国食品和药物管理局（FDA）批准的市售的5％咪喹莫特乳膏所述，被公开和描述。更具体地说，低剂量强度咪喹莫特制剂以比目前美国食品和药物管理局（FDA）批准的给药方案递送有效剂量的咪喹莫特用于治疗光化性角化病，具有可接受的安全性和对患者使用而言更方便的给药方案还公开和描述了用于Aldara 5％咪喹莫特乳膏治疗光化性角化病的“FDA”）。

5. 发明授权

US09078889B2 Lower dosage strength imiquimod formulations and short dosing regimens for treating genital and perianal warts 有权
标题翻译：较低的剂量强度咪喹莫特配方和用于治疗生殖器和肛周疣的短剂量方案
公开(公告)号：US09078889B2
公开(公告)日：2015-07-14
申请号：US14091965
申请日：2013-11-27
申请人： Medicis Pharmaceutical Corporation
发明人： Michael T. Nordsiek , Jefferson J. Gregory
IPC分类号： A01N43/42 , A61K31/44 , A61K31/4745
CPC分类号： A61K31/4745 , A61K9/0014 , A61K9/06 , A61K31/44 , A61K47/10 , A61K47/12
摘要： Pharmaceutical formulations and methods for the topical or transdermal delivery of 1isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine, or 1-(2-methylpropyl)-1H-imidazo[4,5 c]quinolin-4-amine, i.e., imiquimod, to treat genital/perianal warts with shorter durations of therapy than currently prescribed for the commercially available for Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating genital/perianal warts with an acceptable safety profile and dosing regimens that are shorter and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat genital/perianal warts are also disclosed and described.
摘要翻译：用于局部或透皮递送1异丁基-1H-咪唑并[4,5-c] - 喹啉-4-胺或1-（2-甲基丙基）-1H-咪唑并[4,5-c]喹啉-2-酮的药物制剂和方法， 4-胺，即咪喹莫特，以现在由美国食品和药物管理局（FDA）批准的5％咪喹莫特乳膏市售的治疗时间短于治疗的生殖器/肛周疣，被公开和描述。更具体地说，低剂量强度的咪喹莫特制剂，以递送有效剂量的咪喹莫特，用于治疗生殖器/肛周疣，具有可接受的安全性和对于患者使用而言比目前由美国食品和药物当前批准的给药方案更短和更方便的给药方案还公开和描述了用于治疗生殖器/肛周疣的Aldara 5％咪喹莫特乳膏的给药（“FDA”）。

6. 发明授权

US08889154B2 Packaging for 1-(2-methylpropyl)-1H-imidazo[4,5-c] quinolin-4-amine-containing formulation 有权
标题翻译：包装1-（2-甲基丙基）-1H-咪唑并[4,5-c]喹啉-4-胺制剂
公开(公告)号：US08889154B2
公开(公告)日：2014-11-18
申请号：US11530935
申请日：2006-09-12
申请人： Alexis S. Statham , Julie M. Henderson , Kevin G. Lundquist
发明人： Alexis S. Statham , Julie M. Henderson , Kevin G. Lundquist
IPC分类号： A61K9/00 , A01N43/42 , A61K31/44
CPC分类号： A61K31/4745 , A61K9/0014 , A61K47/12
摘要： A packaged composition of 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine dissolved in a fatty acid formulation and contained in a laminated packaging material having a contact layer that includes an acrylonitrile-methyl acrylate copolymer; an outer layer; and a moisture barrier layer disposed between the contact layer and outer layer.
摘要翻译：一种溶解在脂肪酸制剂中的包含在具有接触层的层压包装材料中的1-（2-甲基丙基）-1H-咪唑并[4,5-c]喹啉-4-胺的包装组合物，该接触层包括丙烯腈 - 甲基丙烯酸酯共聚物; 外层; 以及设置在接触层和外层之间的防潮层。

7. 发明授权

US08455512B2 Therapeutic pyrazolyl thienopyridines 有权
标题翻译：治疗性吡唑并噻吩并吡啶类
公开(公告)号：US08455512B2
公开(公告)日：2013-06-04
申请号：US13112520
申请日：2011-05-20
申请人： Stephen D. Barrett , James B. Kramer , Mark L. Boys , Huifen Chen
发明人： Stephen D. Barrett , James B. Kramer , Mark L. Boys , Huifen Chen
IPC分类号： A61K31/4365 , C07D495/04
CPC分类号： C07D495/04 , A61K9/0014 , A61K31/4365
摘要： The present invention provides for compounds of Formula I, and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined therefore in the specification, and pharmaceutically acceptable salts thereof, that are useful as therapeutic agents in the treatment of TGFβ-mediated conditions, including cancer and fibrotic disorders. Also provided are pharmaceutical compositions comprising one or more compounds of Formula I.
摘要翻译：本发明提供式I化合物及其药学上可接受的盐，其中R 1，R 2，R 3，R 4，R 5，R 6和R 7具有在本说明书中定义的任何值及其药学上可接受的盐，可用作治疗TGFbeta介导的病症（包括癌症和纤维化疾病）的治疗剂。还提供了包含一种或多种式I化合物的药物组合物。

8. 发明授权

US08354424B2 Method of treating actinic keratosis 有权
标题翻译：治疗光化性角化病的方法
公开(公告)号：US08354424B2
公开(公告)日：2013-01-15
申请号：US11886204
申请日：2006-03-14
申请人： James H. Lee , Terrance L. Fox
发明人： James H. Lee , Terrance L. Fox
IPC分类号： A61K31/44 , A61K31/4965
CPC分类号： A61K31/4745 , A61K9/0014 , A61K9/06
摘要： A method of treating actinic keratosis including applying topically to an actinic keratosis lesion twice per week for a duration of 8 weeks a formulation comprising 2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine.
摘要翻译：一种治疗光化性角化病的方法，包括每周两次局部应用于光化性角化病病变，持续8周，包含2-甲基-1-（2-甲基丙基）-1H-咪唑并[4,5-c] [1 ，5]萘啶-4-胺。

9. 发明申请

US20120277280A1 PHENOXY-PYRROLIDINE DERIVATIVE AND ITS USE AND COMPOSITIONS 有权
标题翻译：苯氧基吡啶衍生物及其用途和组合物
公开(公告)号：US20120277280A1
公开(公告)日：2012-11-01
申请号：US13549299
申请日：2012-07-13
申请人： Jin Li , Nicole Lee KOLOSKO
发明人： Jin Li , Nicole Lee KOLOSKO
IPC分类号： A61K31/40 , A61P3/00 , A61P35/00 , A61P3/06 , A61P3/10 , A61P3/04 , A61P9/10
CPC分类号： C07D207/12 , A61K31/4025 , C07D207/24
摘要： The present invention is directed to the compound 2-(4-(hydroxymethyl)phenoxy)-1-(3-(2-(trifluoromethyl)phenoxy)pyrrolidin-1-yl)ethanone, its use as an inhibitor of stearoyl CoA desaturase and to pharmaceutical compositions containing this compound.
摘要翻译：本发明涉及化合物2-（4-（羟甲基）苯氧基）-1-（3-（2-（三氟甲基）苯氧基）吡咯烷-1-基）乙酮，其用作硬脂酰CoA去饱和酶的抑制剂，含有该化合物的药物组合物。

10. 发明申请

US20120046576A1 Mid-face aesthetic scale and related methods 审中-公开
标题翻译：中期美学规模及相关方法
公开(公告)号：US20120046576A1
公开(公告)日：2012-02-23
申请号：US13199113
申请日：2011-08-19
申请人： Xiaoming Lin , David Morgan , Ira Lawrence , Mitch Wortzman
发明人： Xiaoming Lin , David Morgan , Ira Lawrence , Mitch Wortzman
IPC分类号： A61B5/103
CPC分类号： A61B5/442 , A45D2044/007 , A61B2576/02
摘要： This disclosure relates to mid-face aesthetic scales and related methods for evaluating fullness in a mid-face area of a human patient's face. In exemplary embodiments, the mid-face area is defined as medial to the maxillary prominence, lateral to the medial canthus, inferior to the maxillary prominence, superior to the plane of nasal alae, and lateral to the nose. An exemplary method for evaluating fullness in a mid-face area of a human patient's face comprises visually comparing a plurality of views of the patient's mid-face against a mid-face scale, and assigning a grade from the scale to the patient's mid-face based on the visual comparison.
摘要翻译：本公开涉及用于评估人类患者面部的中间面积中的丰满度的中间面美学量表和相关方法。在示例性实施例中，中间面积被定义为上颌突出的内侧，侧向于内侧凹陷，低于上颌突起，优于鼻颊平面，并且在鼻侧。用于评估人类患者面部的中间面积中的丰满度的示例性方法包括将患者中间面的多个视图与中等面积比例进行视觉比较，以及将比例的等级分配给患者的中间面基于视觉比较。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式